Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Isunakinra |
| Synonyms | |
| Therapy Description |
Isunakinra (EBI-005) is an IL-1 receptor antagonist (PMID: 23431173) that may block pro-tumor inflammatory responses and lead to tumor inhibition (PMID: 36980752). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Isunakinra | EBI-005 | Isunakinra (EBI-005) is an IL-1 receptor antagonist (PMID: 23431173) that may block pro-tumor inflammatory responses and lead to tumor inhibition (PMID: 36980752). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06634875 | Phase II | Isunakinra | Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS) | Recruiting | USA | 0 |
| NCT04121442 | Phase Ib/II | Isunakinra + unspecified PD-1 antibody Isunakinra Isunakinra + unspecified PD-L1 antibody | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | Completed | USA | 0 |